Amgen tries to block Teva version of Neupogen; Lancet retracts article tying vaccines to autism;

  @FiercePharma: Pharmalot: FDA To Review Safety Of Controversial Dog Drug. Article | Follow @FiercePharma

> The FDA has accepted Teva Pharmaceutical Industries' application to sell a biosimilar version of Amgen's Neupogen, but the biotech giant is working to block the move in court. Report

> Merck and other vaccine makers got a boost from a decision by the British medical journal Lancet to retract a 12-year-old article tying the measles vaccine to autism. Report

> In an opinion reducing punitive damages awarded to a breast cancer survivor by almost $70 million, Judge Norman Ackerman became the first Philadelphia Common Pleas Court judge to uphold a jury finding that Wyeth failed to adequately warn of the dangers of breast cancer from Wyeth's hormonal drugs. Report

> German pharma company Boehringer Ingelheim is not for sale, Chairman Andreas Barner told Frankfurter Allgemeine Zeitung, adding that keeping it in family ownership helps maintain R&D spending at a high level. Report

> The FDA has approved a once-daily antidepressant made by Labopharm, sending its shares up more than 15 percent in premarket trading. Report

Biotech News

 @FierceBiotechAP: Medicis gets FDA nod for pain, wrinkle treatment. Article | Follow @FierceBiotech

 @JohnCFierce: I wonder why any biotech company would have stars in its eyes when it comes to approaching this market with an IPO. | Follow John on Twitter

> Reuters is reporting that France's AB Science is preparing to float an IPO designed to raise $70 million. Report

> Roche CEO offers his vision for new R&D era. Story

> GlaxoSmithKline is willing to wager up to $330 million on an early-stage lung disease drug in Apeiron Biologics' pipeline. Report

> Investors swiftly bid up the value of Neurosearch (NEUR) shares by a whopping 81 percent after hearing that the Danish biotech's Phase III trial of a new drug for Huntington's disease demonstrated real promise. Story

> Ironwood Pharmaceuticals finally made its long-awaited leap into the public market, but ended up falling far short of its very ambitious goal. Report

And Finally... Widely used antidepressants may help patients recover cognitive functions, such as memory skills, that are damaged following a stroke. Report